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I was so pleased to learn that the inaugural
issue of the neonatology specialty section
of Frontiers in Neonatology would high-
light Mary Ellen “Mel” Avery’s contribu-
tions to decades of neonatal research. Mel
was my mentor and friend for more than
30 years, and it is a great honor for me to
write about some of her substantial accom-
plishments. Among her many contribu-
tions, three are especially notable because
they have saved the lives and improved the
health of countless newborns: identifica-
tion of surfactant deficiency as the cause of
respiratory distress syndrome (RDS), treat-
ment of RDS with artificial surfactant, and
prevention of RDS with antenatal steroids.
In a paper she wrote about how it really
happened,Mel dated her interest in respira-
tory physiology to the start of her pediatric
internship at Johns Hopkins in 1952 (1).
Only 1 month after she began her training,
a routine tuberculin skin test that was pos-
itive and a small upper lobe infiltrate on
a chest radiograph consistent with tuber-
culosis prompted a course of antibiotics
and a prescription for 6 months of bed rest.
During this period, questions about her
own treatment spurred her quest for more
knowledge of respiratory physiology.
Returning to her pediatric residency at
Johns Hopkins, Mel cared for many pre-
mature infants with a lung condition then
called hyaline membrane disease (HMD),
and now known as RDS. Nearly half of
the affected infants died, usually in the
first 3 or 4 days, with pathology character-
ized by atelectasis and hyaline membranes
(2). Infants who survived the first few days
typically made a complete recovery.
Mel wanted to learn more about
the lungs of newborn infants, especially
those with HMD. In 1957, following her
residency, she moved to Boston to study
respiratory physiology with Jere Mead
in the Department of Physiology at the
Harvard School of Public Health and to
learn more about newborn infants from
the pediatrician and physiologist Clement
Smith who worked across the street at the
Boston Lying-In Hospital. Military fund-
ing targeted at chemical warfare, especially
the effects of nerve gas on the lung, sup-
ported many laboratories, including those
of Jere Mead, who was studying pulmonary
edema, and John Clements, who was inter-
ested in surface properties of lung extracts.
Clements had modified a surface balance
in order to measure changes in surface ten-
sion with changes in area, as occurs during
breathing. He found that surface tension
of the lung extracts was high when the
area was large, corresponding to higher
lung volumes, and very low when the area
was small, similar to low lung volumes (3).
This was due to a saline extractable surface-
active material at the alveolar air interface
that he named pulmonary surfactant.
Mel visited Clements in Maryland soon
after his publication to learn his tech-
niques. When she returned to Boston,
she and Mead modified Clements’ method
to enable them to study minced extracts
of lungs from human infants that they
obtained from Kurt Benirshke, chief of
pathology at the Boston Lying-In Hospital.
Their observations led to their landmark
publication (4). Using the modified sur-
face balance, Avery and Mead measured
the lowest surface tension obtained with
compression of lung extracts from infants
who died of HMD and infants who died
of other causes. They found low values
in lung extracts from the larger infants
without HMD, similar to older children
or adults, and high values in infants who
died with HMD and in the smallest infants.
They concluded that HMD is caused by the
absence or delayed appearance of a sub-
stance that, when present, would result in a
low surface tension at low lung volume and
thus prevent alveolar collapse.
A second key contribution was Mel’s
role in the translation of her discovery
of surfactant deficiency in HMD to its
clinical application, treatment of affected
newborns with artificial surfactant. In the
1970s, Dr. Tetsuro Fujiwara studied sur-
factant biology with Forrest Adams in Los
Angeles before he returned to Japan to con-
tinue his study of experimental surfactant
replacement. Hearing about his work, Mel
visited Fujiwara in Japan in 1979. At the
time, he was working with a pharmaceuti-
cal company to develop an artificial surfac-
tant from bovine lungs. He subsequently
performed the first study of surfactant
replacement in human infants, reported
the next year (5). Mel returned to Boston to
help plan a randomized trial of surfactant
replacement in the US, using the product
characterized by Fujiwara (6).
That study and others at the time led to a
new era in neonatology. Between 1989 and
1990, infant mortality in the US declined
more rapidly than any other year since
1977, when the rate was much higher. Most
of the decline was in neonatal mortality
which accounts for about two-thirds of
infant deaths, and most in the categories
involving respiration. This was clearly due
to the wide availability of surfactant begin-
ning in July 1989 and followed by rapid
FDA approval in 1990.
A third key contribution was Mel’s work
on prevention of HMD. At a conference in
New Zealand in 1968, she reported that
lungs of fetal lambs less than approxi-
mately 126 days gestation (146 days is full
term) did not retain air. At the same
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FIGURE 1 | Bronchopulmonary tree illustrating Dr. Avery’s trainees through 1984.
meeting, she heard the obstetrician Gra-
ham “Mont” Liggins report treating preg-
nant ewes with corticosteroids to stimulate
early labor. The resultant lambs were born
at a slightly earlier gestational age than
Mel’s (117–123 days) and had well-aerated
lungs, suggesting accelerated appearance of
surfactant, possibly induced by the cor-
ticosteroids. With others, she confirmed
Liggins’ finding of accelerated lung matu-
ration with antenatal steroid administra-
tion in lambs and rabbits (7–9). Liggins
and Howie performed the first randomized
trial of antenatal steroids in humans in
New Zealand (10), and with Bill Taeusch,
Mel participated in an early US human
trial (11).
Mel received many awards for her
extraordinary contributions that led to
understanding the mechanism of RDS
as surfactant deficiency, treatment with
surfactant replacement, and prevention
by antenatal corticosteroid treatment of
women with anticipated preterm birth,
as well as other accomplishments. These
included the Edward Livingston Trudeau
Medal from the American Lung Associ-
ation, the E. Mead Johnson Award from
the Society for Pediatric Research, the John
Howland Award from the American Pedi-
atric Society, and the Virginia Apgar Award
from the American Academy of Pediatrics.
In addition, she was the first pediatrician to
receive the National Medal of Science.
In summary, Mary Ellen Avery was an
outstanding leader in pediatrics for both
her scientific contributions and her sus-
tained efforts to improve health of new-
borns and children in the US and around
the world. In addition, her support and
continued encouragement of the next gen-
eration provides another enduring legacy.
Mel directly mentored at least 75 individ-
uals and influenced many more scientists
and clinicians who have made and continue
to make important contributions and train
others (Figure 1). Those of us who had the
good fortune to work with Mel treasure her
critical insights, imaginative approach, and
personal support.
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